While this pembrolizumab-based regimen is promising and much needed in this patient population, one should remain cognizant of its high costs and the subsequent impact this may have on patients and ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific ...

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

Our team’s strong focus and execution over the last twelve months lay the groundwork for a potential breakthrough year for iTeos in 2025. As we advance multiple trials evaluating belrestotug + ...

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...

Despite a proven survival benefit, the addition of pembrolizumab (Keytruda) to chemoradiotherapy for newly diagnosed locally ...

For nearly 20 years, mesothelioma treatment options were limited to a single regimen: pemetrexed with a platinum agent. Now, there are 3 systemic treatment options available. In this video, Hedy Lee ...

ALX Oncology Holdings Inc.’s ALXO share price has dipped by 19.08%, which has investors questioning if this is right time to buy.